Exercise tolerance with nebivolol and atenolol

Area of Science:

• Cardiology
• Pharmacology
• Exercise Physiology

Background:

• Beta-blocking agents can decrease exercise capacity and increase fatigue in patients.
• Nebivolol is a novel beta-1 adrenoceptor antagonist with a unique hemodynamic profile.
• Optimal antihypertensive dose for nebivolol is established as 5 mg daily.

Purpose of the Study:

• To compare the effects of nebivolol and atenolol on maximal and endurance exercise capacity in healthy volunteers.
• To investigate the hemodynamic and metabolic effects of nebivolol and atenolol during exercise.
• To determine if nebivolol alters exercise capacity compared to atenolol.

Main Methods:

• Double-blind, placebo-controlled, crossover study design.
• Comparison of nebivolol (5 mg daily) and atenolol (100 mg daily) in healthy volunteers.
• Assessment of resting and exercise hemodynamics, maximal and endurance exercise capacity, and metabolic markers.

Main Results:

• Both nebivolol and atenolol similarly reduced resting blood pressure.
• Nebivolol caused a smaller decrease in heart rate compared to atenolol.
• Nebivolol did not decrease maximal or endurance exercise capacity, unlike atenolol, and had less impact on exercise hemodynamics and metabolic responses.

Conclusions:

• Nebivolol, at an antihypertensive dose, does not significantly alter exercise capacity in healthy individuals.
• Nebivolol's preserved exercise capacity may be linked to its distinct hemodynamic and metabolic effects during exercise compared to atenolol.
• These findings suggest a potentially favorable profile for nebivolol in patients concerned about exercise performance during beta-blocker therapy.